Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.69 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.69 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.57 |
| ▸ | RRM1 | P23921 | 1/20 | 0.55 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 4/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | F13A1 | P00488 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | THPO | P40225 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179776 | 1.00 | GNAI3 (0.69) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL12085475 | 1.00 | GNAI3 (0.69) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL5965247 | 0.98 | GNAI3 (0.71) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL5965329 | 0.98 | GNAI3 (0.71) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL7083787 | 0.98 | GNAI3 (0.71) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL5965246 | 0.98 | GNAI3 (0.71) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL5497912 | 0.97 | GNAI3 (0.69) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL5965168 | 0.95 | GNAI3 (0.67) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL5965319 | 0.95 | GNAI3 (0.67) | GNAI3GNAO1GNAI1DPP7RRM1 | |
| SCHEMBL5965169 | 0.93 | GNAI3 (0.64) | GNAI3GNAO1GNAI1DPP7RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096412-A1 | Combination Drug Substance of Polyamine Transport Inhibitor and DFMO | AMINEX THERAPEUTICS, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3785706-A1 | BIOAVAILABLE POLYAMINES | Aminex Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200352983-A1 | BIOAVAILABLE POLYAMINES | AMINEX THERAPEUTICS INC. | 2020-11-12 | — | — | US | disclosed |
| US-10632145-B2 | Bioavailable polyamines | AMINEX THERAPEUTICS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2017165313-A1 | BIOAVAILABLE POLYAMINES | AMINEX THERAPEUTICS INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20170273926-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2017-09-28 | — | — | US | disclosed |
| EP-1373185-B1 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | AMINEX THERAPEUTICS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-RE43327-E1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-RE43327-E1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7432302-B2 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432302-B2 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7208528-B1 | Polyamine analogues as therapeutic and diagnostic agents | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096412-A1 | Combination Drug Substance of Polyamine Transport Inhibitor and DFMO | SLC7A1, SLC19A1, SLC35E1 | GNAI3 3822/4885GNAO1 1156/4885GNAI1 3730/4885 |
| US-20200352983-A1 | BIOAVAILABLE POLYAMINES | SLC7A1, SRM, SLC46A1 | GNAI3 3121/4885GNAO1 3211/4885GNAI1 3122/4885 |
| US-10632145-B2 | Bioavailable polyamines | SLC7A1, SRM, SLC46A1 | GNAI3 3121/4885GNAO1 3211/4885GNAI1 3122/4885 |
| US-20170273926-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, SHMT1 | GNAI3 1394/4885GNAO1 835/4885GNAI1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.